<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schifano F</submitter><funding>Ministry of Education, Universities and Research</funding><pagination>791</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10135331</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(4)</volume><pubmed_abstract>α-Synuclein (αS), dopamine (DA), and iron have a crucial role in the etiology of Parkinson's disease. The present study aims to investigate the interplay between these factors by analyzing the DA/iron interaction and how it is affected by the presence of the C-terminal fragment of αS (Ac-αS&lt;sub>119-132&lt;/sub>) that represents the iron-binding domain. At high DA:Fe molar ratios, the formation of the [Fe&lt;sup>III&lt;/sup>(DA)&lt;sub>2&lt;/sub>]&lt;sup>-&lt;/sup> complex prevents the interaction with αS peptides, whereas, at lower DA:Fe molar ratios, the peptide is able to compete with one of the two coordinated DA molecules. This interaction is also confirmed by HPLC-MS analysis of the post-translational modifications of the peptide, where oxidized αS is observed through an inner-sphere mechanism. Moreover, the presence of phosphate groups in Ser129 (Ac-αS&lt;sup>p&lt;/sup>S&lt;sub>119-132&lt;/sub>) and both Ser129 and Tyr125 (Ac-αS&lt;sup>p&lt;/sup>Y&lt;sup>p&lt;/sup>S&lt;sub>119-132&lt;/sub>) increases the affinity for iron(III) and decreases the DA oxidation rate, suggesting that this post-translational modification may assume a crucial role for the αS aggregation process. Finally, αS interaction with cellular membranes is another key aspect for αS physiology. Our data show that the presence of a membrane-like environment induced an enhanced peptide effect over both the DA oxidation and the [Fe&lt;sup>III&lt;/sup>(DA)&lt;sub>2&lt;/sub>]&lt;sup>-&lt;/sup> complex formation and decomposition.</pubmed_abstract><journal>Antioxidants (Basel, Switzerland)</journal><pubmed_title>Interaction and Redox Chemistry between Iron, Dopamine, and Alpha-Synuclein C-Terminal Peptides.</pubmed_title><pmcid>PMC10135331</pmcid><funding_grant_id>2015T778JW</funding_grant_id><pubmed_authors>Schifano F</pubmed_authors><pubmed_authors>Casella L</pubmed_authors><pubmed_authors>Nicolis S</pubmed_authors><pubmed_authors>Monzani E</pubmed_authors><pubmed_authors>Dell'Acqua S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Interaction and Redox Chemistry between Iron, Dopamine, and Alpha-Synuclein C-Terminal Peptides.</name><description>α-Synuclein (αS), dopamine (DA), and iron have a crucial role in the etiology of Parkinson's disease. The present study aims to investigate the interplay between these factors by analyzing the DA/iron interaction and how it is affected by the presence of the C-terminal fragment of αS (Ac-αS&lt;sub>119-132&lt;/sub>) that represents the iron-binding domain. At high DA:Fe molar ratios, the formation of the [Fe&lt;sup>III&lt;/sup>(DA)&lt;sub>2&lt;/sub>]&lt;sup>-&lt;/sup> complex prevents the interaction with αS peptides, whereas, at lower DA:Fe molar ratios, the peptide is able to compete with one of the two coordinated DA molecules. This interaction is also confirmed by HPLC-MS analysis of the post-translational modifications of the peptide, where oxidized αS is observed through an inner-sphere mechanism. Moreover, the presence of phosphate groups in Ser129 (Ac-αS&lt;sup>p&lt;/sup>S&lt;sub>119-132&lt;/sub>) and both Ser129 and Tyr125 (Ac-αS&lt;sup>p&lt;/sup>Y&lt;sup>p&lt;/sup>S&lt;sub>119-132&lt;/sub>) increases the affinity for iron(III) and decreases the DA oxidation rate, suggesting that this post-translational modification may assume a crucial role for the αS aggregation process. Finally, αS interaction with cellular membranes is another key aspect for αS physiology. Our data show that the presence of a membrane-like environment induced an enhanced peptide effect over both the DA oxidation and the [Fe&lt;sup>III&lt;/sup>(DA)&lt;sub>2&lt;/sub>]&lt;sup>-&lt;/sup> complex formation and decomposition.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-04T11:05:53.638Z</modification><creation>2025-04-04T11:05:53.638Z</creation></dates><accession>S-EPMC10135331</accession><cross_references><pubmed>37107166</pubmed><doi>10.3390/antiox12040791</doi></cross_references></HashMap>